Home LiteratureArticle Details
PMID: 25381811 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer.

Journal of translational medicine ·Vol. 12 ·2014-11-11 ·Pages 304

Zhou J, Min Z, Zhang D, Wang W, Marincola F, Wang X

Abstract

Regulatory T cells (Tregs) and B cells (Bregs) play an important role in the development of lung cancer. The present study aimed to investigate the phenotype of circulating Tregs and Bregs in patients with lung cancer and explore potential mechanism by which lung cancer cells act on the development of both. Patients with lung cancer (n = 268) and healthy donors (n = 65) were enrolled in the study. Frequencies of Tregs and Bregs were measured by flow cytometry with antibodies against CD4, CD25, CD127, CD45RA, CD19, CD24, CD27 and IL-10 before and after co-cultures. qRT-PCR was performed to evaluate the mRNA levels of RANTES, MIP-1α, TGF-β, IFN-γ and IL-4. We found a lower frequency of Tregs and a higher frequency of Bregs in patients with lung cancer compared to healthy donors. Co-culture of lung cancer cells with peripheral blood mononuclear cells could polarize the lymphocyte phenotype in the similar pattern. Lipopolysaccharide (LPS)-stimulated lung cancer cells significantly modulated regulatory cell number and function in an in vitro model. We provide initial evidence that frequencies of peripheral Tregs decreased or Bregs increased in patients with lung cancer, which may be modulated directly by lung cancer cells. It seems cancer cells per se plays a crucial role in the development of tumor immunity.

MeSH Terms
B-Lymphocytes, Regulatory/drug effects,immunology Cell Line, Tumor Chemokine CCL3/metabolism Coculture Techniques Humans Interferon-gamma/metabolism Interleukin-4/metabolism Lipopolysaccharides/pharmacology Lung Neoplasms/immunology,pathology Lymphocyte Activation/immunology Lymphocyte Count NF-kappa B/metabolism RNA, Messenger/genetics,metabolism Signal Transduction/drug effects Tissue Donors Transforming Growth Factor beta/metabolism
Chemicals
Chemokine CCL3 Lipopolysaccharides NF-kappa B RNA, Messenger Transforming Growth Factor beta Interleukin-4 Interferon-gamma
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Zhou Jiebai
Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai, China. doctorbb06@gmail.com.
Min Zhihui
Biomedical Research Center, Zhongshan Hospital, Shanghai, China. minzh1234@163.com. | Fudan University Center for Clinical Bioinformatics, Shanghai, China. minzh1234@163.com.
Zhang Ding
Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai, China. dingzhang0814@sina.com.
Wang William
Department of Biomedical Sciences, UCL, London, UK. william_95a@hotmail.com.
Marincola Francesco
Sidra Medical and Research Centre, Doha, Qatar. fmarincola@sidra.org.
Wang Xiangdong
Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai, China. xiangdong.wang@clintransmed.org. | Biomedical Research Center, Zhongshan Hospital, Shanghai, China. xiangdong.wang@clintransmed.org. | Fudan University Center for Clinical Bioinformatics, Shanghai, China. xiangdong.wang@clintransmed.org.
References (37)
37 references, click to expand
  1. Therapeutic Opportunities for Targeting microRNAs in Cancer.
    Mol Cell Ther. 2014;2(30):1-13 PMID: 25717380
  2. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
    Cancer. 2006 Dec 15;107(12):2866-72 PMID: 17099880
  3. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
    J Immunol. 2002 May 1;168(9):4272-6 PMID: 11970966
  4. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  5. RANTES expression is a predictor of survival in stage I lung adenocarcinoma.
    Clin Cancer Res. 2002 Dec;8(12):3803-12 PMID: 12473593
  6. Killer B lymphocytes: the evidence and the potential.
    Inflamm Res. 2009 Jul;58(7):345-57 PMID: 19262989
  7. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
    Oncol Rep. 2005 Nov;14(5):1269-73 PMID: 16211295
  8. Macrophage inflammatory protein-1 alpha expression in non-neoplastic and neoplastic lung tissue.
    Virchows Arch. 1996 May;428(2):107-11 PMID: 8925123
  9. Immunity, inflammation, and cancer.
    Cell. 2010 Mar 19;140(6):883-99 PMID: 20303878
  10. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.
    Immunity. 2008 May;28(5):639-50 PMID: 18482568
  11. Role of clinical bioinformatics in the development of network-based Biomarkers.
    J Clin Bioinforma. 2011 Oct 24;1(1):28 PMID: 22024468
  12. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity.
    J Immunol. 2010 May 1;184(9):4801-9 PMID: 20368271
  13. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.
    Eur J Immunol. 2001 Apr;31(4):1122-31 PMID: 11298337
  14. CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.
    Cell Cycle. 2009 Aug 15;8(16):2578-85 PMID: 19597336
  15. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.
    Cancer Res. 2011 May 15;71(10):3505-15 PMID: 21444674
  16. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.
    Clin Transl Med. 2014 Mar 29;3(1):7 PMID: 24679154
  17. The global burden of typhoid fever.
    Bull World Health Organ. 2004 May;82(5):346-53 PMID: 15298225
  18. The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states.
    Crit Care. 2010;14(1):R19 PMID: 20156359
  19. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer.
    Ann N Y Acad Sci. 2010 Jan;1183:38-57 PMID: 20146707
  20. Single-cell transcriptome in the identification of disease biomarkers: opportunities and challenges.
    J Transl Med. 2014;12:212 PMID: 25113546
  21. Cancer statistics, 2013.
    CA Cancer J Clin. 2013 Jan;63(1):11-30 PMID: 23335087
  22. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
    J Thorac Oncol. 2011 Mar;6(3):432-8 PMID: 21258248
  23. MicroRNAs: short non-coding players in cancer chemoresistance.
    Mol Cell Ther. 2014 Jun 01;2:16 PMID: 26056584
  24. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
    J Thorac Oncol. 2010 May;5(5):585-90 PMID: 20234320
  25. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.
    Blood. 2011 Jan 13;117(2):530-41 PMID: 20962324
  26. Molecular and Cellular Therapies: New challenges and opportunities.
    Mol Cell Ther. 2013 Nov 06;1:1 PMID: 26056567
  27. Regulatory B cells: evidence, developmental origin and population diversity.
    Mol Immunol. 2010 Nov-Dec;48(1-3):1-8 PMID: 20950861
  28. Metabonomics-based omics study and atherosclerosis.
    J Clin Bioinforma. 2011 Oct 31;1:30 PMID: 22040517
  29. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
    J Immunol Methods. 2007 Apr 30;322(1-2):57-69 PMID: 17382342
  30. Central memory and effector memory T cell subsets: function, generation, and maintenance.
    Annu Rev Immunol. 2004;22:745-63 PMID: 15032595
  31. Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases.
    Clin Transl Med. 2014 Jun 24;3:16 PMID: 24995123
  32. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  33. Cytokines in cancer immunity and immunotherapy.
    Immunol Rev. 2004 Dec;202:275-93 PMID: 15546400
  34. Clinical bioinformatics: a new emerging science.
    J Clin Bioinforma. 2011 Jan 20;1(1):1 PMID: 21884620
  35. Polarized immune responses differentially regulate cancer development.
    Immunol Rev. 2008 Apr;222:145-54 PMID: 18363999
  36. Persistence of naive CD45RA+ regulatory T cells in adult life.
    Blood. 2006 Apr 1;107(7):2830-8 PMID: 16332974
  37. Finding a place for tumor-specific T cells in targeted cancer therapy.
    J Exp Med. 2004 Dec 20;200(12):1533-7 PMID: 15611285
Article Info
Journal
Journal of translational medicine
Abbr.
J Transl Med
ISSN
1479-5876
Published
2014-11-11
Epub
2014-00-11
Pages
304
Language
English
Region
England
NLM ID
101190741
PMCID
PMC4236438
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com